Organon Dividend Information: Key Updates Before Ex-Dividend Date on Aug 15, 2025
Generated by AI AgentAinvest Dividend Digest
Monday, Aug 11, 2025 10:24 pm ET1min read
OGN--
Aime Summary
Organon (OGN) has announced its upcoming dividend details. The ex-dividend date is set for Aug 15, 2025, with the dividend payment scheduled for Sep 11, 2025, at $0.020 per share. Notably, this dividend per share is lower compared to the average of the last ten dividends, which stands at $0.264. The previous dividend was also $0.020 per share, distributed on Jun 12, 2025. Both instances were classified as cash dividends.
Recently, OrganonOGN-- has been in the spotlight following significant developments. Over the past week, the company reported its second-quarter results, revealing a revenue of $1.594 billion and earnings per share that exceeded analyst expectations. This positive financial performance was announced on Aug 5, 2025, and has garnered attention in the investment community.
As of late, Organon has adjusted its 2025 revenue outlook upwards, following a strong financial showing in the second quarter. Analysts indicated that the company's fertility business experienced substantial growth, increasing by 15% excluding foreign exchange effects. This development is seen as a positive indicator of Organon's operational health and future growth prospects.
Since the last update, Organon has also witnessed fluctuations in its stock price. On Aug 11, 2025, the stock experienced a decline of 2.28%, closing at $9.01. This movement has sparked discussion among investors and analysts about the company's market performance and overall valuation.
In conclusion, Organon is navigating a period of significant financial activity and market scrutiny. Investors should be aware that Aug 15, 2025, marks the ex-dividend date, which is the last day to purchase the company's stock to receive the dividend. Any acquisitions made after this date will not be eligible for the current dividend payout.
Recently, OrganonOGN-- has been in the spotlight following significant developments. Over the past week, the company reported its second-quarter results, revealing a revenue of $1.594 billion and earnings per share that exceeded analyst expectations. This positive financial performance was announced on Aug 5, 2025, and has garnered attention in the investment community.
As of late, Organon has adjusted its 2025 revenue outlook upwards, following a strong financial showing in the second quarter. Analysts indicated that the company's fertility business experienced substantial growth, increasing by 15% excluding foreign exchange effects. This development is seen as a positive indicator of Organon's operational health and future growth prospects.
Since the last update, Organon has also witnessed fluctuations in its stock price. On Aug 11, 2025, the stock experienced a decline of 2.28%, closing at $9.01. This movement has sparked discussion among investors and analysts about the company's market performance and overall valuation.
In conclusion, Organon is navigating a period of significant financial activity and market scrutiny. Investors should be aware that Aug 15, 2025, marks the ex-dividend date, which is the last day to purchase the company's stock to receive the dividend. Any acquisitions made after this date will not be eligible for the current dividend payout.

Sip from the stream of US stock dividends. Your income play.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet